Market revenue in 2023 | USD 15,351.1 million |
Market revenue in 2030 | USD 25,815.3 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Novel oral anticoagulants (noacs) |
Fastest growing segment | Heparin and Low Molecular Weight Heparin (LMWH) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Novel Oral Anticoagulants (NOACs), Vitamin K Antagonist, Direct Thrombin Inhibitors, Heparin and Low Molecular Weight Heparin (LMWH) |
Key market players worldwide | Aspen Group Inc, Pfizer Inc, Bristol-Myers Squibb Co, GSK PLC, Sanofi SA, Bayer AG, Boehringer Ingelheim, Daiichi Sankyo Co Ltd, Johnson & Johnson, Eisai Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anticoagulants market will help companies and investors design strategic landscapes.
Novel oral anticoagulants (noacs) was the largest segment with a revenue share of 57.26% in 2023. Horizon Databook has segmented the U.S. anticoagulants market based on novel oral anticoagulants (noacs), vitamin k antagonist, direct thrombin inhibitors, heparin and low molecular weight heparin (lmwh) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. anticoagulants market , including forecasts for subscribers. This country databook contains high-level insights into U.S. anticoagulants market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account